Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tafamidis - Pfizer

Drug Profile

Tafamidis - Pfizer

Alternative Names: Fx-1006A; FX1006A; PF-06291826; PF-6291826; Tafamidis; Tafamidis free acid; Tafamidis meglumine; VYNDAMAX; Vyndaqel

Latest Information Update: 30 May 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator FoldRx Pharmaceuticals
  • Developer Pfizer
  • Class Benzoxazoles; Carboxylic acids; Cardiovascular therapies; Chlorobenzenes; Neuroprotectants; Small molecules
  • Mechanism of Action Amyloid inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cardiomyopathies; Amyloid polyneuropathy
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Amyloid polyneuropathy; Cardiomyopathies

Most Recent Events

  • 05 May 2020 9290914: No updates
  • 28 Mar 2020 Interim adverse events data from a phase III ATTR-ACT trial in cardiomyopathy presented at the 2020 Annual Scientific Session of the American College of Cardiology and World Congress of Cardiology (ACC-WCC-2020)
  • 16 Mar 2020 Registered for Cardiomyopathies (wildtype or hereditary transthyretin amyloid cardiomyopathy) in Australia (PO)
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top